-

Teleflex Publishes 2025 Global Impact Report

Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD).

“This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for our environment, and for our people,” said Cam Hicks, Corporate Vice President and Chief Human Resources Officer. “As the Chair of our CSR Steering Committee, it’s an honor to see the progress we make year over year as we continue to live our purpose to improve the health and quality of people’s lives.”

The 2025 Global Impact Report outlines accomplishments and plans for each of the company’s four CSR pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance.

Highlights from this year’s report include:

  • Climate Risk Assessment: Conducted a Physical Climate Risk Assessment to gain a deeper understanding of exposure to physical climate hazards across our operations and supply chain.
  • Environmental improvements: We continue to make progress on our environmental ambitions including a 41% reduction in hazardous waste, 45% reduction in gas usage and 23% reduction in scope 1 and 2 GHG emissions – all since 2019.
  • Global Health Equity Statement: Created a new Global Health Equity Statement that reflects our objective to enable a greater number of individuals to reach their full health potential.

Read the full 2025 Global Impact Report at https://teleflex.com/usa/en/about-us/csr/index.html.

About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.
© 2026 Teleflex Incorporated. All rights reserved.

Contacts

Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836

Teleflex Incorporated

NYSE:TFX

Release Versions

Contacts

Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836

More News From Teleflex Incorporated

Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during a 30...

Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc (NYSE: MDT). He most recently served as Executive Vice President and President of its Cardiovascular Portf...

Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with a...
Back to Newsroom